Contribution: Industrial Research Assistance Program – Contributions to Firms
OmniaBio Inc.
$75,000.00
Analytics Development to Support Production of CAR-T Cell Therapy
EF 2024-25 · 2024-07-01
Résumé
Three CAR-T Analytics Platforms to Support Production:
1. Development & Optimization of Flow Cytometry Panels for CD19 CAR-T Immunophenotyping
2. Development of a qPCR method for CD19 CAR Gene Expression and Vector Copy Number (VCN)
3. Use of Synthetic Cell Mimics for Tech Transfer of Flow Cytometry Panels from Clients to AD/QC teams at OmniaBio
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Toronto|Toronto, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
777842949
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2025-02-28
Agreement Number
1020634
Agreement Start Date
2024-07-01
Agreement Title
Analytics Development to Support Production of CAR-T Cell Therapy
Agreement Title (French)
Développement analytique pour soutenir la production de la thérapie cellulaire CAR-T
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Three CAR-T Analytics Platforms to Support Production:
1. Development & Optimization of Flow Cytometry Panels for CD19 CAR-T Immunophenotyping
2. Development of a qPCR method for CD19 CAR Gene Expression and Vector Copy Number (VCN)
3. Use of Synthetic Cell Mimics for Tech Transfer of Flow Cytometry Panels from Clients to AD/QC teams at OmniaBio
Description (French)
Trois plateformes d’analyse CAR-T pour soutenir la production : 1. Développement et optimisation de panels de cytométrie en flux pour l’immunophénotypage CAR-T CD19 2. Développement d’une méthode qPCR pour l’expression des gènes CAR CD19 et le nombre de copies de vecteurs (VCN) 3. Utilisation de mimiques de cellules synthétiques pour le transfert technique de panels de cytométrie de flux entre les clients et les équipes AD/QC d’OmniaBio.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
777842949
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
OmniaBio Inc.
Recipient Postal Code
M5G 1M1
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2024-2025-Q2-1020634
